Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Rheumatology

Validation & Orientation: What is Adult-onset Still Disease?

At a Glance

Adult-onset Still Disease (AOSD) is a rare, non-contagious autoinflammatory disorder causing high fevers, joint pain, and a salmon-colored rash. It is a "diagnosis of exclusion" requiring doctors to rule out other conditions using guidelines like the Yamaguchi criteria before starting treatment.

If you are reading this, you have likely just emerged from a period of profound uncertainty. For many, the journey to an Adult-onset Still’s Disease (AOSD) diagnosis feels like a “diagnostic odyssey”—a confusing and often frightening path through multiple specialists and testing for diseases you didn’t have [1][2].

AOSD is a rare systemic autoinflammatory disorder, meaning your body’s innate immune system (your first line of defense) has become overactive without a clear external trigger [3][4]. Because its symptoms—like high spiking fevers, a salmon-colored rash, and joint pain—mimic many other serious conditions, doctors must carefully rule out infections and cancers before confirming AOSD [5][6].

Three Stabilizing Facts

As you begin to navigate this new reality, keep these three essential truths in mind:

  1. The disease is real and it has a name. You are no longer fighting an “unknown” illness. Your symptoms have a documented biological cause, and having a name for your experience is the first step toward reclaiming your health [7].
  2. It is not contagious. AOSD is an internal malfunction of the immune system; it is not an infection and cannot be passed to others [3][8].
  3. There are clear biological targets. Researchers have identified specific proteins, such as Interleukin-1 (IL-1) and Interleukin-6 (IL-6), that drive the inflammation in AOSD [9][4]. Because we know these targets, effective treatments exist to help control the disease [10].

Understanding the Biological Mechanism

At the heart of AOSD is a “hyper-responsive” immune system. Specifically, a complex inside your cells called the NLRP3 inflammasome becomes overactive [11][12]. This complex acts like a factory, pumping out inflammatory signals—primarily cytokines (messenger proteins) like IL-1 and IL-18 [12][13].

These cytokines create a “fire” of inflammation throughout your body, leading to the characteristic high fevers and systemic symptoms [3][9]. Modern treatments are designed to act like “fire extinguishers,” specifically blocking these proteins to bring the inflammation under control [10][14].

Why the Diagnosis Took So Long

AOSD is rare, with an estimated annual incidence of only 0.16 to 0.62 cases per 100,000 people [8][15]. Because it is so uncommon and lacks a single “smoking gun” lab test, it is known as a diagnosis of exclusion [16][2].

Doctors typically use the Yamaguchi criteria, which require a specific combination of major and minor symptoms while ensuring other potential causes have been ruled out [17][16].

  • Major Criteria: High fever (at least 102.2°F), joint pain lasting at least two weeks, a characteristic rash, and a high white blood cell count [17].
  • Minor Criteria: Sore throat, swollen lymph nodes, an enlarged liver or spleen, and specific liver enzyme changes [17].

The time it took to get here was not a failure of your care; it was a necessary process to ensure you received the correct diagnosis for a complex and rare condition [1][2]. Now that you have an answer, you and your medical team can focus on a targeted treatment plan.

Common questions in this guide

What is Adult-onset Still Disease (AOSD)?
AOSD is a rare systemic autoinflammatory disorder where the body's immune system becomes overactive without a clear external trigger. This causes widespread inflammation, leading to symptoms like high fevers, joint pain, and a distinct rash.
Why does it take so long to get an AOSD diagnosis?
Because AOSD is rare and its symptoms mimic many common infections and cancers, doctors must carefully rule out these other conditions first. There is no single blood test for AOSD, making it a diagnosis of exclusion.
What are the Yamaguchi criteria?
The Yamaguchi criteria are a set of guidelines doctors use to diagnose AOSD. They look for a specific combination of major signs like a high fever, prolonged joint pain, a rash, and high white blood cell counts, alongside minor signs like a sore throat and swollen lymph nodes.
What causes the inflammation in AOSD?
In AOSD, an immune system complex called the NLRP3 inflammasome becomes overactive. It acts like a factory pumping out inflammatory messenger proteins, primarily IL-1 and IL-18, creating widespread inflammation throughout the body.
Is Adult-onset Still Disease contagious?
No, AOSD is not contagious. It is caused by an internal malfunction of your own innate immune system, not by a transmissible infection, meaning you cannot pass the disease to anyone else.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specific criteria (like the Yamaguchi or Fautrel criteria) led to my diagnosis of AOSD?
  2. 2.Which 'look-alike' conditions, such as infections or other autoimmune diseases, were ruled out during my diagnostic process?
  3. 3.What are my current levels of inflammatory markers like ferritin, and what do they tell us about my disease activity?
  4. 4.Since IL-1 and IL-6 are primary drivers of this disease, are biological treatments targeting these pathways an option for me?
  5. 5.How will we monitor for potential complications like Macrophage Activation Syndrome (MAS)?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Clinical features and prognosis of adult-onset Still's disease: 75 cases from China.

    Liu Z, Lv X, Tang G

    International journal of clinical and experimental medicine 2015; (8(9)):16634-9.

    PMID: 26629195
  2. 2

    Adult-Onset Still's Disease: A Case Report.

    Shad I, Shafique M, Waris SA, et al.

    Cureus 2022; (14(1)):e21033 doi:10.7759/cureus.21033.

    PMID: 35155001
  3. 3

    A comprehensive review on adult onset Still's disease.

    Giacomelli R, Ruscitti P, Shoenfeld Y

    Journal of autoimmunity 2018; (93()):24-36 doi:10.1016/j.jaut.2018.07.018.

    PMID: 30077425
  4. 4

    Adult-onset Still's disease: A disease at the crossroad of innate immunity and autoimmunity.

    Rao S, Tsang LS, Zhao M, et al.

    Frontiers in medicine 2022; (9()):881431 doi:10.3389/fmed.2022.881431.

    PMID: 36072947
  5. 5

    Still's Disease Onset in Older Adults: Clinical Features, Diagnosis, and Management.

    Tada Y, Maruyama A, Shirahama Y

    Drugs & aging 2024; (41(9)):713-724 doi:10.1007/s40266-024-01137-6.

    PMID: 39097535
  6. 6

    Adult-Onset Still's Disease: Clinical Aspects and Therapeutic Approach.

    Tomaras S, Goetzke CC, Kallinich T, Feist E

    Journal of clinical medicine 2021; (10(4)) doi:10.3390/jcm10040733.

    PMID: 33673234
  7. 7

    EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease.

    Fautrel B, Mitrovic S, De Matteis A, et al.

    Annals of the rheumatic diseases 2024; (83(12)):1614-1627 doi:10.1136/ard-2024-225851.

    PMID: 39317417
  8. 8

    Association between adult-onset still's disease and COVID-19: A report of two cases and brief review.

    Fet-He S, Ibarra Lecompte G, Quiroz Alfaro AJ

    SAGE open medical case reports 2024; (12()):2050313X241233197 doi:10.1177/2050313X241233197.

    PMID: 38404500
  9. 9

    Interleukin-1/6 Blockade for the Treatment of Severe Steroid-Refractory BNT162b2 Vaccine-Induced Adult-Onset Still's Disease.

    Hugues B, Ben Amer H, Bril F, et al.

    European journal of case reports in internal medicine 2022; (9(8)):003469 doi:10.12890/2022_003469.

    PMID: 36093302
  10. 10

    Efficacy and safety of therapies for Still's disease and macrophage activation syndrome (MAS): a systematic review informing the EULAR/PReS guidelines for the management of Still's disease.

    Bindoli S, De Matteis A, Mitrovic S, et al.

    Annals of the rheumatic diseases 2024; (83(12)):1731-1747 doi:10.1136/ard-2024-225854.

    PMID: 39317415
  11. 11

    Anti-NLRP3 Inflammasome Natural Compounds: An Update.

    Liu B, Yu J

    Biomedicines 2021; (9(2)) doi:10.3390/biomedicines9020136.

    PMID: 33535473
  12. 12

    The NLRP3 inflammasome: contributions to inflammation-related diseases.

    Chen Y, Ye X, Escames G, et al.

    Cellular & molecular biology letters 2023; (28(1)):51 doi:10.1186/s11658-023-00462-9.

    PMID: 37370025
  13. 13

    The Role of NLRP3 Inflammasome in Cerebrovascular Diseases Pathology and Possible Therapeutic Targets.

    Bai R, Lang Y, Shao J, et al.

    ASN neuro 2021; (13()):17590914211018100 doi:10.1177/17590914211018100.

    PMID: 34053242
  14. 14

    Anakinra in the management of adult-onset still's disease: a single-center experience.

    Kilic B, Parlar K, Karup S, et al.

    Internal and emergency medicine 2025; (20(1)):131-138 doi:10.1007/s11739-024-03766-6.

    PMID: 39285139
  15. 15

    Advancing Precision Medicine in Adult-Onset Still's Disease: Insights into Biomarkers, Therapies, and COVID-19 Impacts.

    Sahoo DP

    Mediterranean journal of rheumatology 2025; (36(4)):509-523 doi:10.31138/mjr.020525.ahr.

    PMID: 41607599
  16. 16

    Beyond the Norm: A Unique Case of Adult-Onset Still's Disease.

    Attia B, Ismail MS, El-Ghobashy N, et al.

    Cureus 2024; (16(8)):e68104 doi:10.7759/cureus.68104.

    PMID: 39347148
  17. 17

    A case of adult-onset Still's disease in a patient after a car accident.

    Yaman F, Kimiaei A

    Clinical case reports 2023; (11(8)):e7510 doi:10.1002/ccr3.7510.

    PMID: 37614293

This page provides an overview of Adult-onset Still Disease for educational purposes only. It does not replace professional medical advice from your rheumatologist or healthcare team.

Get notified when new evidence is published on Adult-onset Still disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.